首页> 外文期刊>Biotechnology and Applied Biochemistry >Expression and purification of human vascular-endothelialgrowth-factor-receptor-2 tyrosine kinase in Streptomyces for inhibitor screening
【24h】

Expression and purification of human vascular-endothelialgrowth-factor-receptor-2 tyrosine kinase in Streptomyces for inhibitor screening

机译:人血管内皮生长因子受体2酪氨酸激酶在链霉菌中的表达和纯化用于抑制剂筛选

获取原文
获取原文并翻译 | 示例
       

摘要

VEGF (vascular endothelial growth factor) is a critical regulator in angiogenesis through binding to its specific receptors, including VEGFR-2 (VEGF receptor 2), a kinase insert domain-containing receptor, on the surface of endothelial cells. As angiogenesis has been shown to be essential for malignancy of tumours, VEGFR-2 is a potential therapeutic target for the treatment of cancers. To explore this potential, VEGFR-2- CD (the protein tyrosine kinase catalytic domain of VEGFR-2) was cloned and expressed in Streptomyces lividans TK24, a prokaryotic expression system. The recombinant protein was purified, and correlations between its activity and enzyme concentration, ATP concentration, substrate concentration and bivalent cations were characterized. An ELISA-based screening system was then established and used to search for inhibitors acting on the tyrosine kinase part of VEGFR-2. More than 600 compounds originating from a variety of microbes have been screened so far, and a number of them have been demonstrated to be potential inhibitors of VEGFR-2 TK.
机译:VEGF(血管内皮生长因子)通过与血管内皮细胞表面的特定受体(包括VEGFR-2(VEGF受体2),一种含有激酶插入结构域的受体)结合,是血管生成中的关键调节剂。由于血管生成已被证明对于肿瘤的恶性至关重要,因此VEGFR-2是治疗癌症的潜在治疗靶标。为了探索这种潜力,克隆了VEGFR-2-CD(VEGFR-2的蛋白酪氨酸激酶催化结构域)并在原核表达系统lividans TK24中进行了表达。纯化了重组蛋白,并表征了其活性与酶浓度,ATP浓度,底物浓度和二价阳离子之间的相关性。然后建立了基于ELISA的筛选系统,并用于搜索作用于VEGFR-2酪氨酸激酶部分的抑制剂。迄今为止,已经筛选了600多种源自多种微生物的化合物,其中许多已被证明是VEGFR-2 TK的潜在抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号